E133: Obinutuzumab for SLE (ALLEGORY)
About this episode
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast
E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast
E130: Telitacicept for SLE
The Evidence Based Rheumatology Podcast
E129: Long Term Routine Laboratory Monitoring in RA
The Evidence Based Rheumatology Podcast